Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
Holding RNA?
Track your performance easily
RNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.15 - $50.78
Previous Close$45.09
Volume1.27M
Average Volume (3M)1.29M
Market Cap
$5.25B
Enterprise Value$3.96B
Total Cash (Recent Filing)$1.30B
Total Debt (Recent Filing)$8.38M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.95
Shares Outstanding118,220,000
10 Day Avg. Volume812,184
30 Day Avg. Volume1,292,947
Standard Deviation0.23
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.57
Price to Sales (P/S)502.93
Price to Cash Flow (P/CF)-20.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue373.50
Enterprise Value/Gross Profit414.09
Enterprise Value/Ebitda-15.05
Forecast
1Y Price Target
$66.40Price Target Upside40.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Avidity Biosciences News
PremiumCompany Announcements
Avidity Biosciences Reports Strong Q3 Progress and Outlook
Bulls Say, Bears Say
Bulls Say
Clinical Trials And DevelopmentThe initiation of a biomarker cohort is designed to support potential accelerated approval for RNA's del-brax treatment.
Financial StrengthThe company is well capitalized for future development with cash and cash equivalents of approximately $1.6 billion.
Regulatory And ApprovalThe removal of the del-desiran partial clinical hold clears any lingering doubt on the regulatory status of the DM1 program.
Bears Say
Adverse EventsOne patient discontinued due to a serious anaphylaxis event and another due to a moderate infusion-related reaction.
Clinical TrialsMinimal information has been shared thus far about the novel DUX4 regulated endpoint.
Safety ConcernsIn Sep 2022, del-desiran Ph1/2 MARINA was placed on partial clinical hold due to treatment-related SAE of bilateral stroke in 1 patient in 4mg/kg cohort.
---
Ownership Overview
1.24% Insiders
29.12% Mutual Funds
0.83% Other Institutional Investors
53.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNA FAQ
What was Avidity Biosciences Inc’s price range in the past 12 months?
Avidity Biosciences Inc lowest stock price was $5.15 and its highest was $50.78 in the past 12 months.
What is Avidity Biosciences Inc’s market cap?
Currently, no data Available
When is Avidity Biosciences Inc’s upcoming earnings report date?
Avidity Biosciences Inc’s upcoming earnings report date is Mar 04, 2025 which is in 115 days.
How were Avidity Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is Avidity Biosciences Inc overvalued?
According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued.
Does Avidity Biosciences Inc pay dividends?
Avidity Biosciences Inc does not currently pay dividends.
What is Avidity Biosciences Inc’s EPS estimate?
Avidity Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avidity Biosciences Inc have?
Avidity Biosciences Inc has 117,121,400 shares outstanding.
What happened to Avidity Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avidity Biosciences Inc?
Among the largest hedge funds holding Avidity Biosciences Inc’s share is RA Capital Management. It holds Avidity Biosciences Inc’s shares valued at 221M.
---
Avidity Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.40 (40.56% Upside)
$66.40 (40.56% Upside)
Blogger Sentiment
Bullish
RNA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
791.32%
12-Months-Change
Fundamentals
Return on Equity
-28.36%
Trailing 12-Months
Asset Growth
120.61%
Trailing 12-Months
Company Description
Avidity Biosciences Inc
Avidity Biosciences Inc is a bio-technology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.
---
RNA Stock 12 Month Forecast
Average Price Target
$66.40
▲(40.56% Upside)
Technical Analysis
Scholar Rock Holding
―
Fulcrum Therapeutics
―
Seres Therapeutics
―
Bolt Biotherapeutics
―
Best Analysts Covering RNA
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+162.02%
reiterated a buy rating 11 days ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +162.02% per trade.
---